Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival (Q36287951)

13 August 2017

Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival (English)

1 reference

13 August 2017

1 reference

Y S Yap

1

1 reference

13 August 2017

G H Cornelio

2

1 reference

13 August 2017

B C R Devi

3

1 reference

13 August 2017

C Khorprasert

4

1 reference

13 August 2017

S B Kim

5

1 reference

13 August 2017

T Y Kim

6

1 reference

13 August 2017

S C Lee

7

1 reference

13 August 2017

Y H Park

8

1 reference

13 August 2017

J H Sohn

9

1 reference

13 August 2017

N Sutandyo

10

1 reference

13 August 2017

D W Y Wong

11

1 reference

13 August 2017

M Kobayashi

12

1 reference

13 August 2017

S H Landis

13

1 reference

13 August 2017

E M Yeoh

14

1 reference

13 August 2017

H Moon

15

1 reference

13 August 2017

J Ro

16

1 reference

13 August 2017

language of work or name

English

0 references

publication date

23 August 2012

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

107

1 reference

13 August 2017

7

1 reference

13 August 2017

1075-1082

1 reference

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

The natural history of breast cancer patients with brain metastases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3461152

Adenoid cystic carcinoma, low-differentiation carcinoma, squamous cell carcinoma: a rare evolution of a tracheal malignancy within 27 years.

22 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.346

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.346

Extended survival in women with brain metastases from HER2 overexpressing breast cancer

21 January 2018

1 reference

12 December 2020

Survival in patients with brain metastases from breast cancer: the importance of HER-2 status

1 reference

12 December 2020

1 reference

12 December 2020

Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment

1 reference

12 December 2020

Defining prognosis for women with breast cancer and CNS metastases by HER2 status

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.346

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

PubMed publication ID

22918394

1 reference